FindTrial
Sign In

CYH33

DRUG4 trials

Sponsors

Haihe Biopharma Co., Ltd.

Conditions

Advanced Breast CancerBreast CancerEndometrial CancerOvarian CancerPIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)Prostate CancerRecurrent Cancer

Phase 1

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
TerminatedNCT04586335
Haihe Biopharma Co., Ltd.Breast Cancer, Endometrial Cancer, Ovarian Cancer +2
Start: 2020-09-28End: 2023-02-15Updated: 2024-03-21
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
NCT04856371
Haihe Biopharma Co., Ltd.Advanced Breast Cancer
Start: 2021-04-30End: 2022-12-31Target: 228Updated: 2021-04-23
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
RecruitingNCT06975618
Haihe Biopharma Co., Ltd.PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)
Start: 2023-08-22End: 2029-12-31Target: 141Updated: 2026-06-29

Phase 2

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Active, not recruitingNCT05043922
Haihe Biopharma Co., Ltd.Ovarian Cancer, Recurrent Cancer
Start: 2021-10-11End: 2026-02-28Updated: 2026-01-30

Related Papers

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with <i>PIK3CA</i>-mutated, HR+/HER2- advanced breast cancer.
Journal of Clinical Oncology2024-05-291 citations
An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group
JMA Journal2023-01-013 citations
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Nature Communications2022-11-1617 citations